Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta (lefamulin), recently approved by the FDA for both Oral and IV use and CONTEPO (fosfomycin) for injection, we submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.
Nabriva is a commercial-stage biopharmaceutical company with locations in the
United States (King of Prussia, PA, San Diego, CA), Austria (Vienna), and Ireland (Dublin), home of our corporate headquarters.
Nabriva is a commercial-stage biopharmaceutical company with locations in the
United States (King of Prussia, PA, San Diego, CA), Austria (Vienna), and Ireland (Dublin), home of our corporate headquarters.
Location: Ireland, Dublin
Employees: 51-200
Total raised: $120M
Founded date: 2006
Investors 8
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.04.2015 | Series B | $120M | - |
Mentions in press and media 11
| Date | Title | Description |
| 26.05.2021 | Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP) | - Lefamulin was shown to be non-inferior to moxifloxacin, with 76.8% of lefamulin-treated patients meeting the efficacy endpoint of Investigator Assessment of Clinical Response (IACR) at Test of Cure (TOC), compared to 71.4% of patients tre... |
| 26.04.2021 | Vienna: Europe’s underestimated innovation hotspot | Austria ~ Company: With almost 200 000 highly-educated and multi-linguistic students, out of which 30% are international talents, attractive geographical location at the heart of CEE, a population with high purchasing power which makes for ... |
| 20.12.2019 | Nabriva Therapeutics Announces $20 Million Registered Direct Offering | - |
| 21.02.2017 | Ally Bridge Group Expands European Life Science Portfolio with New Investments and Establishes Presence in Europe | HONG KONG and ZUG, Switzerland, Feb. 21, 2017 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading global cross-border healthcare investment group, announced that in recent months it has completed investments in two European biopharmaceutica... |
| 01.09.2016 | Zavante Therapeutics Secures $10 Million Loan | Zavante Therapeutics, a San Diego startup launched by biotech veterans last fall, has secured a $10 million loan from Square 1 Bank, a division of Pacific Western Bank. The new funds will be used for growth and commercialization, according ... |
| 30.03.2016 | Zavante Therapeutics Closes $45 Million Series A Financing In Support Of U.S. Development For A First-In-Class Injectable Antibiotic | SAN DIEGO, March 30, 2016 /PRNewswire/ — Zavante Therapeutics, Inc., a privately held, late clinical-stage biopharmaceutical company, today announced that it has closed a $45 million Series A financing, consisting of $35 million from new in... |
| 30.03.2016 | Zavante raises $45M to bring antibiotic fosfomycin to U.S. | However, there’s nothing like fosfomycin on the U.S. market, CEO Ted Schroeder said in a phone interview. The drug’s a first-in-class epoxide injectable antibiotic that’s shown, for decades, activity against both Gram-positive and Gram-nega... |
| 08.04.2015 | Nabriva Therapeutics raises $120M for drugs that attack antibiotic resistant bacteria that cause pneumonia | “We believe Nabriva is one of a few development stage companies with a truly novel antibiotic product ready for phase 3 studies and with a clear path to commercialization,” Dr. Chen Yu, a managing partner at Vivo Capital, said in a statemen... |
| 07.04.2015 | Nabriva Therapeutics Completes $120M Series B Financing | Nabriva Therapeutics AG, a Vienna, Austria- and Philadelphia, PA-based biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram... |
| 28.10.2009 | Austrian Nabriva Therapeutics Raises €15M in Equity Financing | Nabriva Therapeutics, a Vienna, Austria-baseed biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens, announced the closing of a €15M financing from existing investors in... |
Show more